ArticleJBRA assisted reproduction2025
Hypogonadotropic Hypogonadism in a Central Obesity Patient with 46, XY, t(1; 10)(q42; q24).
Article in JBRA assisted reproduction, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypogonadotropic hypogonadism (HH) is characterized by absent or insufficient secretion of GnRH and/or pituitary gonadotropins, which consequently leads to testicular dysfunction. HH is commonly associated with obesity, particularly in specific genetic syndromes, and its etiology appears heterogeneous and remains far from fully understood. This report describes the case of a 31-year-old male with HH and central obesity, who has a karyotype of 46, XY, t(1; 10)(q42; q24). He demonstrated a good pituitary response to GnRH as well as a robust testicular reserve in both the GnRH stimulation test and the hCG stimulation test. Notably, he exhibited no lifestyle risk factors for obesity or comorbidities likely contributing to his condition. The SCD1 gene, located at 10q24.31, promotes the synthesis of fatty acids, and its abnormality may play a significant role in the pathogenesis of obesity. We propose that the translocation between chromosome 1q42 and chromosome 10q24 may disrupt the function of SCD1 at chromosome 10q24, resulting in the mutually reinforcing relationship between obesity and HH in this patient.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.